BioSpace News Archive

Alebund Pharmaceuticals, a biopharmaceutical company dedicated to developing innovative therapies for the treatment of renal diseases and related chronic conditions, announced that it has raised $60 million in its Series B financing round which was led by Quan Capital, and followed by a prominent sovereign wealth fund, 3E Bioventures Capital, and Sherpa Healthcare Partners.

Telix Pharmaceuticals Limited announces it has been granted Human Research Ethics Committee approval and received Clinical Trial Notification clearance by the Australian Therapeutic Goods Administration to commence a Phase III clinical trial of the Company’s PSMA1 targeted prostate cancer therapy candidate TLX591, in patients with advanced metastatic castrate-resistant prostate cancer.